Key is a combination of existing shareholders understanding the potential value of the drug ( reduces selling & increases buying & holding ) whilst management execute clinical strategy carefully with significant effort put into education of potential investors. Obviously in parallel to marketing to big pharma ( or just before ) they will pop above the radar to draw in international smart money biotech funds.
Transparency in reporting of trials plans and results ( either preclinical or clinical ) also important for building shareholder confidence.
The SP run in the next 6 months is shaping up to be epic.
The tight share register will play a big part. I’m looking forward to next quarterly being released for stats on change in distribution.
Ann: Notification regarding unquoted securities - RAC, page-54
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.010(0.62%) |
Mkt cap ! $279.4M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.66 | $1.61 | $195.8K | 120.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1749 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 783 | 1 |
View Market Depth
| Last trade - 13.15pm 29/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |